The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback